PARP inhibitors (PARPis) exhibit a synthetic lethal effect in cells with deficiencies in HR repair, such as those with mutations in Breast Cancer gene 1 or 2 (BRAC1, BRAC2) as they rely heavily on the PARP-mediated alt-NHEJ pathway to repair DSBs. This evidence concerns the gene PARP1 and cancer.